|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
(none)
|
|
INDICATIONS:
|
|
Ascorbic acid deficiency |
|
Scurvy |
|
Urinary acidification |
| |
|
|
SIDE EFFECTS:
|
|
Kidney stones, oxalate |
|
Dizziness or faintness |
|
Diarrhea |
|
flushing or redness of skin |
|
headache |
|
increase in urination, mild |
|
nausea or vomiting |
|
stomach cramps |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Diabetes mellitus |
|
Glucose-6-phosphate dehydrogenase deficiency |
|
Hemochromatosis |
|
Sideroblastic anemia |
|
Thalassemia |
|
Hyperoxaluria |
|
Renal stones |
|
|
ADULT DOSE:
|
|
Deficiency (prophylaxis)-Oral, amount based on normal daily recommended intakes:
Persons U.S. Canada
(mg) (mg)
Adolescent and adult males 50-60 25-40
Adolescent and adult females 50-60 25-30
Pregnant females 70 30-40
Breast-feeding females 90-95 55
Smokers 100 45-60
Deficiency (treatment)-Treatment dose is individualized by prescriber based on severity of deficiency. The following dosage has been established: Scurvy-Oral, 500 mg a day for at least 2 weeks. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Deficiency(prophylaxis)-Oral, amount based on intake of normal daily recommended intakes:
Persons U.S. Canada
(mg) (mg)
Infants and children 30-40 20
Birth to 3 years of age
4 to 6 years of age 45 25
7 to 10 years of age 45 25
Deficiency (treatment)-Treatment dose is individualized by prescriber based on severity of deficiency. The following dosage has been established: Scurvy-Oral, 100 to 300 mg a day for at least 2 weeks. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|